HAVCR2 and ovarian cancer: The aim of the review was to analyze studies considering the expression of TIM-3 and LAG-3 (Figure 1) in the ovarian cancer microenvironment and considering immunotherapy for ovarian cancer that includes antibodies directed against TIM-3 and LAG-3.